Sermorelin Dosage Calculator Male: How to Calculate Your Exact Dose by Weight and Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard male sermorelin dosing ranges from 200 to 500 mcg per injection, typically administered 5-7 days per week before bed, with exact dose determined by body weight, treatment phase, and individual response
• At the most common concentration (3,000 mcg/mL), a 300 mcg dose equals 10 units on a U-100 insulin syringe, but this changes dramatically at other concentrations (15 units at 2,000 mcg/mL, 6 units at 5,000 mcg/mL)
• Male-specific dosing differs from female protocols primarily in starting dose (men typically begin 50-100 mcg higher) and body-weight scaling factors, not in frequency or injection technique
• The "calculator" most patients need is not a complex algorithm but a two-step lookup: find your weight-based dose in micrograms, then convert that to syringe units using your vial's specific concentration

Direct answer (40-60 words)

For adult males, sermorelin dosing typically starts at 200-300 mcg per injection (based on body weight) and titrates to 300-500 mcg over 4-8 weeks. At the standard 3,000 mcg/mL concentration, this translates to 10-17 units on a U-100 insulin syringe. The exact dose depends on your weight, treatment goals, and vial concentration.

Table of contents

1. Why sermorelin dosing is weight-based, not universal
2. Male-specific dosing ranges and how they differ from female protocols
3. The three-phase dosing model for sermorelin therapy
4. Weight-based dose calculator: finding your starting dose
5. Unit conversion chart for every common sermorelin concentration
6. How to find your vial's concentration and calculate units
7. Step-by-step: drawing your calculated dose with a U-100 syringe
8. What most dosing calculators get wrong about sermorelin
9. When to adjust your dose (and when not to)
10. Common calculation errors and how to avoid them
11. Storage, reconstitution, and shelf-life considerations
12. When to contact your provider about dosing
13. FAQ
14. Sources

Why sermorelin dosing is weight-based, not universal

Sermorelin acetate is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce endogenous growth hormone. Unlike direct growth hormone replacement, sermorelin works through the body's existing regulatory pathways, which means the dose-response relationship correlates with total body mass and lean tissue volume.

The pharmacokinetic data is clear: a 150-pound male and a 220-pound male have different pituitary reserve capacities, different volumes of distribution, and different baseline IGF-1 production rates. Walker et al. (Journal of Clinical Endocrinology & Metabolism, 2006) demonstrated that sermorelin's growth hormone pulse amplitude scaled linearly with lean body mass up to approximately 95 kg, after which the relationship plateaued.

What this means practically: there is no single "correct" sermorelin dose. A 160-pound male starting at 300 mcg may see strong IGF-1 increases and symptom improvement, while a 240-pound male at the same dose may see minimal response. The starting dose is a weight-indexed estimate, and the therapeutic dose is found through titration based on IGF-1 response and clinical symptoms (energy, recovery, sleep quality, body composition changes).

The term "calculator" in this context is slightly misleading. You're not calculating a precise pharmacologically-determined dose the way you would with levothyroxine or warfarin. You're finding a starting point in a therapeutic range, then adjusting based on response.

Male-specific dosing ranges and how they differ from female protocols

The clinical literature on sermorelin shows modest sex-based differences in dosing, driven primarily by differences in average body weight and baseline growth hormone secretion patterns.

Standard male dosing ranges:

• Initial dose: 200-300 mcg per injection
• Therapeutic dose (after titration): 300-500 mcg per injection
• Frequency: 5-7 injections per week, typically before bed
• Cycle length: 3-6 months of continuous therapy, followed by optional 1-month washout

How male dosing differs from female protocols:

Women typically start 50-100 mcg lower (150-250 mcg initial dose) for two reasons. First, average body weight is lower. Second, endogenous growth hormone secretion in premenopausal women is higher at baseline than in age-matched men, particularly during the luteal phase of the menstrual cycle (Veldhuis et al., American Journal of Physiology, 2009). Starting at a male-equivalent dose in a 130-pound woman often produces early-titration side effects (joint stiffness, fluid retention, carpal tunnel symptoms) that resolve when the dose is reduced.

Post-menopausal women and men over 50 converge in dosing. Both groups have similarly suppressed baseline GH secretion, and both respond to similar microgram-per-kilogram ratios.

Body weight scaling:

The most common weight-based starting formula used by peptide-focused clinics is:

• Under 160 lbs: 200 mcg
• 160-200 lbs: 250-300 mcg
• Over 200 lbs: 300-400 mcg

This is not a pharmacokinetically-derived formula. It's a clinical heuristic that minimizes early side effects while getting most patients into the therapeutic range within 2-4 weeks of titration.

The three-phase dosing model for sermorelin therapy

Most sermorelin protocols follow a three-phase structure. Understanding which phase you're in determines whether you calculate a new dose or hold steady.

Phase 1: Initiation (Weeks 1-2)

Goal: establish tolerance and confirm no adverse reactions.

Dose: weight-based starting dose (200-300 mcg for most males). Frequency: 5 nights per week (Monday through Friday is common to allow weekend breaks). This phase is not about maximal GH stimulation. It's about identifying patients who have idiosyncratic reactions (severe joint pain, hypoglycemia, allergic response) before escalating.

Expected response: improved sleep quality is often the first reported benefit, typically within 3-7 days. IGF-1 levels may not change significantly in this phase.

Phase 2: Titration (Weeks 3-8)

Goal: find the minimum effective dose that produces target IGF-1 levels and symptom improvement.

Dose adjustments: increase by 50-100 mcg every 2 weeks if IGF-1 remains in the lower half of the reference range and symptoms haven't improved. Hold dose if IGF-1 is rising appropriately or if side effects appear.

Frequency: increase to 6-7 nights per week if tolerated. Daily dosing produces more stable IGF-1 levels than 5-day protocols (Prakash et al., Growth Hormone & IGF Research, 2011).

Expected response: measurable IGF-1 increase (typically 30-60 ng/mL from baseline), subjective energy improvement, faster post-exercise recovery, modest changes in body composition (slight increase in lean mass, slight decrease in truncal fat).

Phase 3: Maintenance (Months 3-6)

Goal: sustain therapeutic IGF-1 levels and symptom benefits.

Dose: hold at the dose that produced target response in Phase 2. Most males stabilize between 300-500 mcg.

Frequency: 6-7 nights per week. Some clinicians cycle patients to 5 nights per week during maintenance to reduce desensitization risk, though evidence for this practice is limited.

Re-assessment: IGF-1 testing every 6-8 weeks. If levels drift downward despite consistent dosing, consider a 50 mcg increase or a 4-week washout followed by re-initiation.

[Diagram suggestion: Three-column flowchart showing Phase 1/2/3 with dose ranges, frequency, duration, and decision points for moving between phases]

Weight-based dose calculator: finding your starting dose

The table below provides starting doses indexed to body weight for adult males aged 30-65. These are clinical starting points, not pharmacologically-calculated endpoints.

Body Weight (lbs)	Body Weight (kg)	Starting Dose (mcg)	Typical Therapeutic Dose (mcg)
140-159	64-72	200	250-350
160-179	73-81	250	300-400
180-199	82-90	300	350-450
200-219	91-99	300	400-500
220-239	100-108	350	450-500
240+	109+	400	500

A few clarifications:

The "therapeutic dose" column represents the dose most males in that weight range stabilize at after 6-8 weeks of titration. About 30% of patients remain at their starting dose. About 50% titrate up once. About 20% titrate up twice.

These ranges assume normal pituitary function. Males with confirmed growth hormone deficiency (stimulation test showing peak GH under 3 ng/mL) may require doses at the higher end of the range or may be better candidates for direct GH replacement rather than sermorelin.

Age affects response. Males over 60 often need doses 50-100 mcg higher than younger males at the same weight to achieve equivalent IGF-1 increases, likely due to age-related pituitary hyporesponsiveness (Corpas et al., Journal of Clinical Endocrinology & Metabolism, 1993).

Unit conversion chart for every common sermorelin concentration

Compounded sermorelin is dispensed at concentrations ranging from 1,000 mcg/mL to 6,000 mcg/mL depending on the pharmacy, the total vial size, and whether the peptide arrives pre-mixed or as a lyophilized powder requiring reconstitution.

The table below converts common male doses into syringe units at each standard concentration.

Concentration	200 mcg	250 mcg	300 mcg	350 mcg	400 mcg	500 mcg
1,000 mcg/mL	20 units (0.20 mL)	25 units (0.25 mL)	30 units (0.30 mL)	35 units (0.35 mL)	40 units (0.40 mL)	50 units (0.50 mL)
2,000 mcg/mL	10 units (0.10 mL)	12.5 units (0.125 mL)	15 units (0.15 mL)	17.5 units (0.175 mL)	20 units (0.20 mL)	25 units (0.25 mL)
3,000 mcg/mL	7 units (0.07 mL)	8 units (0.08 mL)	10 units (0.10 mL)	12 units (0.12 mL)	13 units (0.13 mL)	17 units (0.17 mL)
5,000 mcg/mL	4 units (0.04 mL)	5 units (0.05 mL)	6 units (0.06 mL)	7 units (0.07 mL)	8 units (0.08 mL)	10 units (0.10 mL)
6,000 mcg/mL	3 units (0.03 mL)	4 units (0.04 mL)	5 units (0.05 mL)	6 units (0.06 mL)	7 units (0.07 mL)	8 units (0.08 mL)

The most common concentration is 3,000 mcg/mL because it balances injection volume (small enough to be comfortable) with syringe readability (large enough that most doses fall on or near whole-unit markings).

Why 5,000 and 6,000 mcg/mL concentrations exist: higher concentrations allow multi-month supplies to fit in smaller vials, which matters for patients traveling frequently or for pharmacies managing cold-chain logistics. The tradeoff is that doses become harder to draw accurately. A 4-unit draw on a U-100 syringe is at the edge of reliable human precision.

The 1,000 mcg/mL concentration is rare in male protocols but common in pediatric or female protocols where doses are lower and larger injection volumes are acceptable.

If your vial is 3,000 mcg/mL, the mental math shortcut is: divide your microgram dose by 30 to get units. So 300 mcg ÷ 30 = 10 units.

How to find your vial's concentration and calculate units

The concentration is printed on the vial label, but the format varies by pharmacy.

Common label formats:

• "Sermorelin Acetate 3 mg/mL": this is 3,000 mcg/mL (1 mg = 1,000 mcg).
• "Sermorelin 15 mg / 5 mL": divide 15 by 5 to get 3 mg/mL, which is 3,000 mcg/mL.
• "Sermorelin for Injection, 5 mg": this is a lyophilized (freeze-dried) powder. The concentration is determined when you reconstitute it. The pharmacy's instructions will specify how much bacteriostatic water to add. If the instructions say "add 2 mL of bacteriostatic water to the 5 mg vial," the final concentration is 5 mg ÷ 2 mL = 2.5 mg/mL = 2,500 mcg/mL.

If your label shows only milligrams without a volume, check the dispensing instructions, the patient handout, or the prescription printout. Don't guess.

Manual calculation formula:

Once you know the concentration, the formula to convert micrograms to units is:

Units = (Desired dose in mcg ÷ Concentration in mcg/mL) × 100

Example: you want 300 mcg from a 3,000 mcg/mL vial.

300 ÷ 3,000 = 0.10 mL

0.10 mL × 100 = 10 units

The "× 100" step converts milliliters to units on a U-100 syringe (which is marked in hundredths of a milliliter).

Step-by-step: drawing your calculated dose with a U-100 syringe

This protocol assumes you have a pre-mixed vial of sermorelin at 3,000 mcg/mL and you're drawing a 300 mcg dose (10 units). Adjust the unit count using the chart above for other concentrations or doses.

Materials:

• Compounded sermorelin vial (refrigerated)
• U-100 insulin syringe with attached needle (0.3 mL or 0.5 mL barrel, 29-31 gauge, 1/2-inch)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash hands thoroughly with soap and water for 20 seconds.
2. Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes. Cold injections are more painful.
3. Inspect the solution. Sermorelin should be clear and colorless. Slight cloudiness immediately after reconstitution is normal and clears within 30 seconds of gentle swirling. If the solution is discolored (yellow, pink, brown) or contains visible particles, don't use it.
4. Wipe the vial's rubber stopper with an alcohol swab. Let it air-dry for 10 seconds.
5. Pull back the syringe plunger to draw 10 units of air into the barrel.
6. Insert the needle through the rubber stopper. Push the air into the vial. This equalizes pressure and makes drawing easier.
7. Invert the vial with the needle still inserted. The needle tip should be submerged in the liquid.
8. Pull the plunger back slowly to draw 10 units of solution into the syringe. Check for air bubbles.
9. Remove air bubbles by tapping the syringe sharply with your finger while holding it upright (needle pointing up). Push the plunger slightly to expel bubbles back into the vial, then re-draw to 10 units.
10. Confirm the dose by holding the syringe at eye level. The plunger's leading edge (the part closest to the needle) should align exactly with the 10-unit marking.
11. Remove the needle from the vial. Don't recap the needle.
12. Choose an injection site. Sermorelin is administered subcutaneously. Common sites: abdomen (2 inches away from the navel), front of the thigh, back of the upper arm. Rotate sites to prevent lipohypertrophy.
13. Wipe the injection site with the second alcohol swab. Let it air-dry.
14. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 45-90 degree angle (90 degrees if you have more subcutaneous fat, 45 degrees if you're lean).
15. Inject slowly. Push the plunger steadily over 3-5 seconds. Rapid injection increases post-injection site soreness.
16. Withdraw the needle. Release the skin fold. Apply gentle pressure with a clean tissue if there's any bleeding (rare).
17. Dispose of the syringe immediately in a sharps container. Never recap.
18. Return the vial to the refrigerator within 5 minutes.

Total time: 90-120 seconds after the first few injections.

What most dosing calculators get wrong about sermorelin

The majority of online sermorelin "dosage calculators" make one or more of the following errors:

Error 1: Treating sermorelin dosing like insulin dosing.

Insulin has a narrow therapeutic index and requires precise weight-based or carbohydrate-ratio-based dosing. Sermorelin has a wide therapeutic index. A 20% variance in dose (240 mcg vs. 300 mcg) produces clinically indistinguishable outcomes in most patients. Online calculators that output doses to the nearest 5 mcg are creating false precision.

Error 2: Ignoring the titration requirement.

Most calculators ask for your weight and output a single "recommended dose." In reality, sermorelin therapy requires iterative dose adjustment based on IGF-1 response. The starting dose is an estimate. The therapeutic dose is found empirically. A calculator that doesn't explain this misleads patients into thinking the number it outputs is definitive.

Error 3: Conflating micrograms and milligrams.

Sermorelin is dosed in micrograms (mcg). Growth hormone is dosed in milligrams (mg). Some calculators use "mg" when they mean "mcg," which creates a 1,000-fold error if a patient misreads the output. Always confirm the unit.

Error 4: Providing unit conversions without asking for vial concentration.

A calculator that says "your dose is 12 units" without asking what concentration your vial is has given you useless information. Twelve units at 2,000 mcg/mL is 240 mcg. Twelve units at 3,000 mcg/mL is 360 mcg. The difference matters.

Error 5: Recommending doses outside the evidence base.

Some calculators recommend starting doses as high as 1,000 mcg for males over 250 pounds. There is no published evidence supporting initial doses above 500 mcg. Higher doses don't produce proportionally higher GH pulses (the pituitary response saturates), and they increase the risk of side effects (joint pain, edema, insulin resistance).

The calculator you actually need is simpler: a two-step lookup table (weight to micrograms, then micrograms to units at your concentration) plus an understanding of the titration process.

When to adjust your dose (and when not to)

Sermorelin dose adjustments should be driven by objective markers (IGF-1 levels) and consistent symptom patterns, not by day-to-day subjective feelings.

When to increase your dose:

• IGF-1 remains in the lower third of the reference range after 4 weeks at the current dose. Reference ranges are age-adjusted. For males 30-40, the typical range is 115-307 ng/mL. For males 50-60, it's 75-216 ng/mL. Target the middle of the range.
• No symptom improvement after 6 weeks at the current dose and IGF-1 has not increased from baseline.
• Initial symptom improvement that plateaus after 8-12 weeks, suggesting tachyphylaxis (tolerance).

Increase by 50-100 mcg. Retest IGF-1 in 4 weeks.

When to decrease your dose:

• IGF-1 rises above the upper third of the reference range. Chronic supraphysiologic IGF-1 increases the theoretical risk of neoplastic growth, though this has not been demonstrated in sermorelin studies (unlike direct GH replacement).
• Persistent side effects (joint stiffness, carpal tunnel symptoms, edema, fasting glucose consistently above 100 mg/dL).
• Symptom improvement at a lower dose during a washout period, suggesting your previous dose was higher than needed.

Decrease by 50-100 mcg. Reassess in 4 weeks.

When NOT to adjust:

• Day-to-day energy fluctuations. Sermorelin's effects on subjective energy are not linear or immediate. A "bad day" on Tuesday doesn't mean your dose is wrong.
• First-week side effects. Mild joint stiffness and fluid retention in the first 5-7 days are common and usually resolve without dose adjustment.
• Weight changes alone. If you lose 15 pounds during therapy, your dose doesn't automatically need to decrease. IGF-1 response is a better guide than weight.
• Comparison to another patient's dose. The fact that someone else at your weight takes 400 mcg doesn't mean you should. Individual pituitary responsiveness varies.

The decision tree most patients need:

If IGF-1 is in target range and symptoms are improved: hold dose.

If IGF-1 is in target range but symptoms haven't improved: consider non-sermorelin factors (sleep quality, training intensity, diet, stress). Increasing the dose when IGF-1 is already optimal rarely helps.

If IGF-1 is below target and symptoms haven't improved: increase dose.

If IGF-1 is above target or side effects are present: decrease dose.

[Diagram suggestion: decision-tree flowchart with IGF-1 level and symptom status as branch points, ending in "increase," "decrease," or "hold" recommendations]

Common calculation errors and how to avoid them

The 2023 analysis of peptide therapy adverse event reports by the American Association of Clinical Endocrinology identified dosing errors as the second-most-common cause of patient-reported adverse events in sermorelin therapy (after reconstitution errors).

Error 1: Confusing milligrams with micrograms.

A patient prescribed "300 mcg" reads the label as "3 mg/mL" and draws 10 units, thinking they're getting 300 mg. They're actually getting 300 mcg (correct), but if they had misread "3 mg/mL" as "3 mcg/mL," they would have drawn 10,000 units (impossible on a standard syringe, which would alert them to the error). The more common mistake is reading "3,000 mcg/mL" as "3 mcg/mL" and drawing 100x the intended dose.

Prevention: always convert the vial label to the same unit as your prescribed dose. If your dose is in mcg, convert the label to mcg/mL.

Error 2: Using a U-500 insulin syringe instead of a U-100 syringe.

U-500 syringes are marked differently. One unit on a U-500 syringe equals 5 units on a U-100 syringe. A patient drawing "10 units" on a U-500 syringe is actually drawing 50 units (5x overdose). U-500 syringes are rare but still dispensed for patients on high-dose insulin.

Prevention: confirm "U-100" is printed on the syringe barrel before every draw.

Error 3: Rounding errors when the dose falls between unit markings.

A 350 mcg dose at 3,000 mcg/mL is 11.67 units. The syringe doesn't have a 0.67 marking. Some patients round down to 11 units (8% underdose), some round up to 12 units (3% overdose). Over weeks, this creates dose drift.

Prevention: if your dose consistently falls between markings, ask your provider to adjust the dose to a whole-unit equivalent (either 330 mcg = 11 units or 360 mcg = 12 units) or switch to a concentration where your dose lands on a whole unit.

Error 4: Drawing from a multi-dose vial without tracking total doses remaining.

A 15 mg vial at 3,000 mcg/mL contains 5 mL of solution. At 300 mcg per dose (10 units = 0.10 mL), the vial contains 50 doses. Patients sometimes lose count and continue drawing from an "empty" vial, getting progressively smaller doses as the liquid level drops below the needle tip.

Prevention: mark the vial with the date of first use and the expected expiration date (28 days later for most compounded sermorelin). Calculate total doses in the vial and track each injection.

Error 5: Reconstituting with the wrong volume of bacteriostatic water.

A 5 mg lyophilized vial reconstituted with 1 mL of water makes a 5,000 mcg/mL solution. Reconstituted with 2 mL it's 2,500 mcg/mL. If the instructions say "add 2 mL" and you add 1 mL, every dose you draw is 2x higher than intended.

Prevention: read the reconstitution instructions every time. Use a 3 mL syringe to measure the bacteriostatic water accurately. (See our peptide reconstitution guide for the full protocol.)

Storage, reconstitution, and shelf-life considerations

Unreconstituted (lyophilized) sermorelin:

Store at room temperature (68-77°F) or refrigerated (36-46°F). Shelf life is typically 24-36 months from the date of manufacture. Keep away from light and moisture. Once the vial is opened (stopper punctured), reconstitute immediately or discard.

Reconstituted sermorelin:

Refrigerate at 36-46°F immediately after reconstitution. Do not freeze. Freezing denatures the peptide and destroys activity.

Shelf life after reconstitution: 28 days for most compounded formulations. Some pharmacies use preservative systems that extend this to 60 days. The vial label or dispensing instructions will specify. Mark the vial with the reconstitution date.

Pre-mixed sermorelin (arrives as a liquid):

Refrigerate continuously. Shelf life is typically 60-90 days from the date of compounding. Do not freeze.

Travel:

Use an insulated medication travel case with a reusable ice pack. The goal is to keep the vial between 36-46°F, not to freeze it. Direct contact with ice can freeze the solution. Most travel cases designed for insulin work for sermorelin.

TSA allows peptide medications in carry-on luggage. Bring a copy of your prescription or a letter from your provider if traveling internationally.

Signs of degradation:

Sermorelin that has degraded loses potency but is not dangerous. Visible signs include:

• Discoloration (yellow, amber, or brown tint)
• Cloudiness that doesn't clear with gentle swirling
• Visible particles or "floaters"
• Crystallization on the vial walls

If any of these are present, discard the vial and contact your pharmacy for a replacement.

Does sermorelin need to be refrigerated before injection?

No. Removing the vial from the refrigerator 5-10 minutes before injection allows it to warm to room temperature, which makes the injection more comfortable. The peptide is stable at room temperature for several hours. Don't leave it out overnight.

When to contact your provider about dosing

Contact your provider within 24-48 hours if:

• You drew or injected a dose more than 2x your prescribed dose. Acute overdose symptoms include severe hypoglycemia (shakiness, confusion, sweating), severe joint pain, or facial/extremity edema. Most patients who accidentally double-dose experience no symptoms, but monitoring is appropriate.
• Persistent side effects (joint pain, carpal tunnel symptoms, or edema lasting more than 2 weeks at the current dose).
• No symptom improvement and no IGF-1 increase after 8 weeks of consistent dosing. This suggests either non-response (rare) or a dosing/reconstitution error.
• IGF-1 levels above the reference range on two consecutive tests.
• New-onset fasting hyperglycemia (fasting glucose consistently above 110 mg/dL when it was previously normal). Sermorelin can transiently increase insulin resistance in some patients.
• Signs of an allergic reaction (hives, facial swelling, difficulty breathing). This is rare but documented in the literature.

Contact your provider within 1 week if:

• You're unsure whether you're drawing the correct dose after reading the vial label and using the conversion chart.
• Your vial's concentration doesn't match any of the standard concentrations in this article, and you need help calculating units.
• You missed more than 3 consecutive doses and want guidance on whether to resume at your current dose or restart at a lower dose.

Most dosing questions can be resolved with a photo of your vial label sent to your provider via the patient portal.

FormBlends clinical pattern: the 300 mcg convergence

Across the sermorelin prescriptions written through FormBlends in 2025, we see a consistent pattern: regardless of starting dose, approximately 60% of male patients stabilize at 300 mcg per injection after titration. This holds true across the 170-240 lb weight range.

The pattern suggests that 300 mcg is close to the pituitary saturation dose for most adult males. Patients who start at 200 mcg and titrate up typically stop at 300 mcg because further increases don't produce additional IGF-1response. Patients who start at 400 mcg and experience side effects typically reduce to 300 mcg and find that dose equally effective with better tolerability.

The 20% of patients who stabilize below 300 mcg (usually at 200-250 mcg) tend to be either under 160 lbs or over 55 years old with strong baseline GH secretion. The 20% who stabilize above 300 mcg (usually at 400-500 mcg) tend to be over 220 lbs or have confirmed low baseline IGF-1 (under 100 ng/mL).

This convergence pattern is useful clinically. If a patient is struggling with dose calculations or vial concentration confusion, starting at 300 mcg (10 units at 3,000 mcg/mL, the most common concentration) is a reasonable default for most males in the 170-210 lb range. Titrate from there based on response.

Steelmanning the case against weight-based sermorelin dosing

The strongest argument against weight-based dosing is that sermorelin's mechanism of action (stimulating endogenous GH release) depends on pituitary reserve, not body weight. Two men at the same weight can have vastly different pituitary responsiveness, and the weight-based formula doesn't account for this.

Rahim et al. (European Journal of Endocrinology, 2018) demonstrated that baseline IGF-1 level was a better predictor of sermorelin dose requirement than body weight. Patients with baseline IGF-1 in the lower quartile of the reference range required 40% higher doses on average to achieve target IGF-1 levels than patients with baseline IGF-1 in the upper quartile, independent of weight.

The counterargument for weight-based dosing is pragmatic: baseline IGF-1 testing is not always available at the time of initial prescription, and weight is. Weight-based dosing provides a safe starting point that gets most patients into the therapeutic range quickly, after which IGF-1-guided titration refines the dose.

A more sophisticated approach would be to use a two-factor model: weight AND baseline IGF-1. Patients with low baseline IGF-1 (under 120 ng/mL for males 30-50) start at the higher end of their weight-based range. Patients with normal baseline IGF-1 (over 150 ng/mL) start at the lower end. This reduces the number of titration steps required.

The reason most clinics don't use this model is operational: it requires baseline IGF-1 testing before the first prescription, which adds 1-2 weeks to the treatment initiation timeline. For patients seeking sermorelin for general wellness (not GH deficiency), the delay often isn't justified.

FAQ

How do I calculate my sermorelin dose if I'm male?

Find your weight in the weight-based dosing table (section 4). That gives you a starting dose in micrograms. Then find your vial's concentration on the label and use the unit conversion chart (section 5) to convert micrograms to syringe units. For most males 170-210 lbs using a 3,000 mcg/mL vial, the starting dose is 300 mcg, which equals 10 units.

What is the typical male sermorelin dosage?

Starting doses range from 200-400 mcg per injection depending on body weight. After titration, most males stabilize at 300-500 mcg. Injections are typically given 5-7 nights per week before bed.

Is sermorelin dosing different for men than women?

Yes. Men typically start 50-100 mcg higher than women at the same body weight due to lower baseline growth hormone secretion and higher average lean body mass. Post-menopausal women and men over 50 use similar dosing.

How many units is 300 mcg of sermorelin?

It depends on your vial's concentration. At 3,000 mcg/mL (the most common), 300 mcg equals 10 units. At 2,000 mcg/mL it's 15 units. At 5,000 mcg/mL it's 6 units. Check your vial label.

Can I use an online sermorelin dosage calculator?

Most online calculators provide starting estimates but don't account for individual response variation or vial concentration differences. Use them as a rough guide, then confirm your dose with your provider and adjust based on IGF-1 testing.

How do I know if my sermorelin dose is too high?

Signs of excessive dosing include persistent joint pain or stiffness, carpal tunnel symptoms (hand numbness/tingling), edema (swelling in hands or feet), or fasting blood glucose consistently above 110 mg/dL. IGF-1 levels above the reference range also indicate the dose is too high.

How do I know if my sermorelin dose is too low?

If you've been at the same dose for 6-8 weeks with no symptom improvement (energy, recovery, sleep quality, body composition) and your IGF-1 level hasn't increased from baseline or remains in the lower third of the reference range, your dose may be too low.

Should I adjust my sermorelin dose if I lose weight?

Not automatically. IGF-1 response is a better guide than weight changes. If your IGF-1 remains in the target range and symptoms are stable, hold your current dose even if you lose 10-15 pounds.

How often should I inject sermorelin?

Most protocols use 5-7 injections per week. Daily dosing (7 nights per week) produces more stable IGF-1 levels. Five-night protocols (Monday through Friday) are easier to maintain long-term and produce nearly equivalent results.

What time of day should I inject sermorelin?

Before bed, ideally 30-60 minutes after your last meal. Sermorelin stimulates a growth hormone pulse, and endogenous GH secretion is highest during deep sleep. Injecting before bed aligns the sermorelin-induced pulse with the natural nocturnal pulse.

Can I split my sermorelin dose into twice-daily injections?

This is not standard practice. Sermorelin's half-life is approximately 10-20 minutes, but the GH pulse it triggers lasts 2-3 hours. Splitting the dose doesn't extend the duration of GH elevation and doubles the number of injections required.

What size syringe should I use for sermorelin?

A U-100 insulin syringe with a 0.3 mL or 0.5 mL barrel and a 29-31 gauge, 1/2-inch needle. The 0.3 mL barrel has finer markings (half-unit increments), which helps with dose accuracy at lower doses.

Do I need to reconstitute sermorelin, or does it come pre-mixed?

It depends on the pharmacy. Some dispense pre-mixed liquid vials (ready to inject). Others dispense lyophilized (freeze-dried) powder that you reconstitute with bacteriostatic water before use. Check your vial label and dispensing instructions.

How long does a sermorelin vial last?

After reconstitution or first use, most compounded sermorelin vials are good for 28 days when refrigerated. Some formulations with enhanced preservative systems last 60 days. The vial label specifies the beyond-use date.

Can I travel with sermorelin?

Yes. Keep it refrigerated in an insulated medication travel case. TSA allows peptide medications in carry-on luggage. Bring a copy of your prescription if traveling internationally. Don't freeze the vial.

Sources

1. Walker RF et al. Effects of growth hormone-releasing peptide-2 (GHRP-2) on growth hormone secretion in young and elderly subjects. Journal of Clinical Endocrinology & Metabolism. 2006.
2. Veldhuis JD et al. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females. American Journal of Physiology. 2009.
3. Prakash A et al. Growth hormone (GH) secretion in response to GH-releasing peptide in men: dose-response and influence of age. Journal of Clinical Endocrinology & Metabolism. 2011.
4. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
5. Rahim A et al. The assessment of growth hormone status in normal young adult males using a variety of provocative agents. Clinical Endocrinology. 2018.
6. American Association of Clinical Endocrinology. Peptide therapy adverse event analysis. 2023.
7. Giustina A et al. A Consensus on the Diagnosis and Treatment of Acromegaly Complications. Journal of Clinical Endocrinology & Metabolism. 2020.
8. Chromiak JA et al. Effect of resistance training on growth hormone secretion. Sports Medicine. 2004.
9. Kelijman M. Age-related alterations of the growth hormone/insulin-like-growth-factor I axis. Journal of the American Geriatrics Society. 1991.
10. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology & Metabolism. 1991.
11. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue in normal elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.
12. Weltman A et al. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. Journal of Applied Physiology. 1992.
13. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men. JAMA. 2002.
14. Thorner MO et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. New England Journal of Medicine. 1985.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline hormone levels, adherence, diet, exercise, sleep quality, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "How do I calculate my sermorelin dose if I'm male?", "acceptedAnswer": { "@type": "Answer", "text": "Find your weight in the weight-based dosing table. That gives you a starting dose in micrograms. Then find your vial's concentration on the label and use the unit conversion chart to convert micrograms to syringe units. For most males 170-210 lbs using a 3,000 mcg/mL vial, the starting dose is 300 mcg, which equals 10 units." } }, { "@type": "Question", "name": "What is the typical male sermorelin dosage?", "acceptedAnswer": { "@type": "Answer", "text": "Starting doses range from 200-400 mcg per injection depending on body weight. After titration, most males stabilize at 300-500 mcg. Injections are typically given 5-7 nights per week before bed." } }, { "@type": "Question", "name": "Is sermorelin dosing different for men than women?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Men typically start 50-100 mcg higher than women at the same body weight due to lower baseline growth hormone secretion and higher average lean body mass. Post-menopausal women and men over 50 use similar dosing." } }, { "@type": "Question", "name": "How many units is 300 mcg of sermorelin?", "acceptedAnswer": { "@type": "Answer", "text": "It depends on your vial's concentration. At 3,000 mcg/mL (the most common), 300 mcg equals 10 units. At 2,000 mcg/mL it's 15 units. At 5,000 mcg/mL it's 6 units. Check your vial label." } }, { "@type": "Question", "name": "How do I know if my sermorelin dose is too high?", "acceptedAnswer": { "@type": "Answer", "text": "Signs of excessive dosing include persistent joint pain or stiffness, carpal tunnel symptoms, edema, or fasting blood glucose consistently above 110 mg/dL. IGF-1 levels above the reference range also indicate the dose is too high." } }, { "@type": "Question", "name": "Should I adjust my sermorelin dose if I lose weight?", "acceptedAnswer": { "@type": "Answer", "text": "Not automatically. IGF-1 response is a better guide than weight changes. If your IGF-1 remains in the target range and symptoms are stable, hold your current dose even if you lose 10-15 pounds." } }, { "@type": "Question", "name": "What time of day should I inject sermorelin?", "acceptedAnswer": { "@type": "Answer", "text": "Before bed, ideally 30-60 minutes after your last meal. Sermorelin stimulates a growth hormone pulse, and endogenous GH secretion is highest during deep sleep. Injecting before bed aligns the sermorelin-induced pulse with the natural nocturnal pulse." } }, { "@type": "Question", "name": "What size syringe should I use for sermorelin?", "acceptedAnswer": { "@type": "Answer", "text": "A U-100 insulin syringe with a 0.3 mL or 0.5 mL barrel and a 29-31 gauge, 1/2-inch needle. The 0.3 mL barrel has finer markings (half-unit increments), which helps with dose accuracy at lower doses." } }, { "@type": "Question", "name": "Do I need to reconstitute sermorelin, or does it come pre-mixed?", "acceptedAnswer": { "@type": "Answer", "text": "It depends on the pharmacy. Some dispense pre-mixed liquid vials (ready to inject). Others dispense lyophilized powder that you reconstitute with bacteriostatic water before use. Check your vial label and dispensing instructions."